Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
You may also be interested in...
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using artificial intelligence and machine learning.